Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Pneuma Systems Corporation Recruits Industry Pioneer to Disrupt Home Infusion Space

Infusion therapy at home vital to a $20 billion worldwide market

Pneuma Systems Corporation (Pneuma), an emerging leader in the infusion therapy industry, announced it appointed Stanley N. Chamallas, RPh  FASHP FNHIA, as its Director of Infusion Therapy Process Improvement for Home Care.

Read More About AI News : AI Innovation Supports Rural and Remote Internet Connectivity

Mr. Chamallas was one of a handful of pioneering pharmacists that created the now well-established field of home infusion therapy. Just over 40 years ago, when options for treating patients at home were very limited, Chamallas helped develop early methods for bulk preparation of intravenous nutrition products. He contributed to nearly every aspect of home infusion with Home Health Care of America, which evolved into Caremark and subsequently was acquired by Baxter International. Since then, Chamallas contributed to many commercial and industry organizations, both large and small, until his retirement from OptionCare Health, a current leader in home infusion services.

Related Posts
1 of 40,404

Browse The Complete News About Aithority : Snowplow Expands Global Operations with Opening of Boston Office

Pneuma plans to support a network of Centers of Infusion Excellence where therapies are carried out in controlled environments under intense observation. Traditional outpatient treatments will be accompanied by procedures for home and acute care, carried out in simulated environments.

“I have long envisioned creating a streamlined process for drug delivery, but the technology never supported it,” said Mr. Chamallas. “The approach by Pneuma is different; they look at the entire process rather than just a product. It reminds me of the transformation with Uber, in which all the ‘friction’ has been removed from a process. I was very active in the initial use of ‘elastomeric infusion pumps,’ which had a positive impact on patient care, and I’m eager to be part of an effort that can have an even larger impact.”

Top Artificial Intelligence InsightsDetermining the Potential of Your AI Algorithm Starts with Measurement

[To share your insights with us, please write to sghosh@martechseries.com]

Comments are closed.